Immunic AG | WebDisclosure

Basculer en Français

8296	Companies
114899	Keywords
55318	Articles
62453	Press releases

Home
Companies
Immunic AG

BRIEF

published on 11/13/2024 at 12:35, 8 days ago

Immunic publie les données de l'essai de phase 1/1b de l'IMU-856 dans The Lancet

Essai Clinique Immunique IMU-856 Maladie Cœliaque Gastroentérologie
BRIEF

published on 11/13/2024 at 12:35, 8 days ago

Immunic Publishes Phase 1/1b Trial Data of IMU-856 in The Lancet

Clinical Trial Immunic Gastroenterology IMU-856 Celiac Disease
PRESS RELEASE

published on 11/13/2024 at 12:30, 8 days ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
Immunic announces publication of phase 1/1b clinical trial data of IMU-856 in The Lancet Gastroenterology & Hepatology. Positive results in celiac disease patients. Potential new approach for gastrointestinal diseases

Gastrointestinal Diseases Clinical Trial Immunic IMU-856 Celiac Disease
BRIEF

published on 11/07/2024 at 12:35, 14 days ago

Immunic, Inc. publie ses résultats financiers du troisième trimestre 2024

Résultats Financiers Vidofludimus Calcique Essais ENSURE De Phase 3 Recherche Sur La Sclérose En Plaques Mises À Jour Des Essais Cliniques
BRIEF

published on 11/07/2024 at 12:35, 14 days ago

Immunic, Inc. Reports Q3 2024 Financial Results

Financial Results Vidofludimus Calcium Phase 3 ENSURE Trials Multiple Sclerosis Research Clinical Trial Updates
PRESS RELEASE

published on 11/07/2024 at 12:30, 14 days ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Immunic, Inc. reports Q3 2024 financial results, positive Phase 3 ENSURE Program interim analysis. Twin Phase 3 ENSURE trials and Phase 2 CALLIPER trial on track. Webcast held on Nov 7. IMUX stock update

Financial Results Immunic Inc. Q3 2024 Phase 3 ENSURE Program IMUX Stock
BRIEF

published on 10/31/2024 at 11:35, 21 days 1 hour ago

Immunic, Inc. to Release Q3 2024 Financial Results and Corporate Update

Financial Results Biotechnology Clinical Trials Webcast Immunic
BRIEF

published on 10/31/2024 at 11:35, 21 days 1 hour ago

Immunic, Inc. publiera ses résultats financiers du troisième trimestre 2024 et une mise à jour de l'entreprise

Résultats Financiers Biotechnologie Webcast Essais Cliniques Immunique
PRESS RELEASE

published on 10/31/2024 at 11:30, 21 days 1 hour ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
Immunic, Inc. (Nasdaq: IMUX) to release Q3 financial results and corporate update on Nov 7, 2024. Webcast at 8:00 am ET. Company developing therapies for inflammatory and autoimmune diseases. Visit www.imux.com for more info

Financial Results Biotechnology Corporate Update Immunic Inc. Clinical Pipeline
BRIEF

published on 10/29/2024 at 11:35, 23 days 1 hour ago

Immunic to Participate in Key Conferences Throughout November

Investors Biotechnology Clinical Trials Conférences Immunic

1 2 ... 6

Accesswire

Published on 11/21/2024 at 13:00, 19 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 19 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 19 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 13:00, 19 minutes ago

Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Published on 11/21/2024 at 13:00, 19 minutes ago

Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 12:35, 44 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 4 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 13 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 19 minutes ago

Holding(s) in Company
Published on 11/21/2024 at 11:30, 1 hour 49 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 21 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 21 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 21 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 17 hours 12 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 59 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE